NCT02666352View on ClinicalTrials.gov

A Study of the Pharmacokinetics of Uprifosbuvir (MK-3682) and Ruzasvir (MK-8408) in Participants With Moderate and Severe Hepatic Insufficiency (MK-3682-029)

PHASE1CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

January 22, 2016

Primary Completion Date

January 16, 2017

Study Completion Date

January 16, 2017

Conditions
Hepatitis C, Chronic
Interventions
DRUG

Uprifosbuvir

A single dose of uprifosbuvir 450 mg (given as three 150-mg tablets) taken by mouth.

DRUG

Ruzasvir

A single dose of ruzasvir 60 mg (given as six 10-mg capsules) taken by mouth.

All Listed Sponsors
lead

Merck Sharp & Dohme LLC

INDUSTRY

NCT02666352 - A Study of the Pharmacokinetics of Uprifosbuvir (MK-3682) and Ruzasvir (MK-8408) in Participants With Moderate and Severe Hepatic Insufficiency (MK-3682-029) | Biotech Hunter | Biotech Hunter